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While cancer-free survival has improved over the past 20 years for many individuals with prostate, renal, breast, and
hematologic malignancies, the increasingly recognized prevalence of cardiovascular (CV) events in cancer survivors
has been an unintended consequence of many of the therapies that have improved these survival rates. The
increase in CV events threatens to offset the improvement in cancer related survival. As a result, there is an
emerging need to develop methods to identify those individuals treated for cancer at increased risk of
cardiovascular events. With its inherent ability to characterize myocardial tissue and identify both cardiac and
vascular dysfunction, cardiovascular magnetic resonance (CMR) has the potential to identify both subclinical and
early clinical CV injury before the development of an overt catastrophic event such as a myocardial infarction,
stroke, or premature cardiac death. Early identification provides an opportunity for the implementation of primary
prevention strategies to prevent such events, thereby improving overall cancer survivorship and quality of life. This
article reviews the etiology of CV events associated with cancer therapy and the unique potential of CMR to
provide early diagnosis of subclinical CV injury related to the administration of these therapies.
Keywords: Cardiotoxicity, Chemotherapy, Cancer, Cardiovascular magnetic resonanceReview
Over the past 20 years, cancer free survival has im-
proved for many individuals with prostate, renal, breast,
and hematologic malignancies. Unfortunately, an unin-
tended consequence of many of the therapies that have
contributed to this improvement in cancer-free survival
has been the increasingly recognized evolution of car-
diovascular (CV) events [1-12]. Several recently pub-
lished research studies provide insight into possible
etiologies of these events. Result from studies involving the
Centers for Medicare-Medicaid Services (CMS) and Health
Maintenance Organization (HMO) databases within the
United States indicate an increased prevalence of billing
codes for heart failure, myocardial infarction (MI), and* Correspondence: ghundley@wakehealth.edu
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distribution, and reproduction in any mediumcardiac arrhythmias in patients treated for cancer [1-12].
Also in these studies, there is an increased frequency of
codes related to the administration of chemotherapy for
cancer that precedes the onset of codes for CV disease and
events. The fact that chemotherapy codes precede CV
event codes in cancer patients implies a temporal relation-
ship between the administration of cancer treatment and
the subsequent occurrence of CV events.
Importantly, the number of cancer survivors who ex-
perience subsequent CV events is large. In the US alone,
there are now over 13 million cancer survivors, and for
breast cancer alone, it is estimated that over $800 mil-
lion will be spent annually providing CV care for these
women [2-4]. As a result, there is an emerging need to
develop accurate, cost-effective methods to identify
those individuals treated for cancer at increased risk of
CV events.
Cardiovascular magnetic resonance (CMR) with its
inherent ability to characterize myocardial tissue andentral Ltd. This is an Open Access article distributed under the terms of the
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potential to identify both subclinical and early clinical
CV injury before the development of an overt catastrophic
event such as a MI, stroke or premature cardiac death.
Early identification of subclinical CV injury provides an
opportunity for the implementation of primary prevention
strategies to prevent these untoward CV events. By redu-
cing CV related events in those treated for cancer, the
opportunity exists to improve overall cancer survivorship.
In this article, we review the data indicating an increased
incidence of CV events in cancer survivors, the underlying
mechanisms of these events, and the potential of CMR to
provide early diagnosis of subclinical CV injury related to
the administration of therapy for cancer, and there-
fore to guide therapeutic interventions to reduce the
overall CV related mortality and morbidity associated
with therapy for cancer.
Cardiovascular injury and disease after cancer treatment
The 5-year survival rate for patients with breast cancer
or hematologic malignancies has increased from an aver-
age of 53% in 2007, to upwards of 85% in 2012 [13,14].
While encouraging, this positive trend in improved
cancer-related mortality is tempered by an emerging in-
crease in CV disease, morbidity, and mortality [8]. The
reasons for this increase in CV related events are uncer-
tain; however, the results from several studies suggest
that this emergence may be related to the therapies
utilized to treat the cancer. Several therapeutic inter-
ventions including the administration of chemother-
apy [15], immunotherapy [16], hormone deprivation [17]
and radiation related therapy [18,19] have been associated
with CV related increases in morbidity or mortality. The
injuries and abnormalities associated with cancer treat-
ment can be highly variable and depend on the type of
cancer treatment received. In Table 1, a review of the
agents previously associated with CV injury is provided.
Below, we briefly discuss three categories of agents associ-
ated with CV events.
Myocellular injury due to anthracycline chemotherapy
In children or adults treated for a hematologic malig-
nancy or women treated for breast cancer, the adminis-
tration of anthracyclines has been associated with left
ventricular (LV) dysfunction and heart failure [9,20]. In
the Childhood Cancer Survivor Study (CCSS) cohort,
which includes children and young adults <21 years of
age who received chemotherapy beginning in 1994,
childhood cancer survivors experienced a relative risk
(RR) of 15.1 (95% confidence interval [CI] 4.8-47.9) of de-
veloping congestive heart failure (CHF) when compared
to their siblings without cancer or receipt of chemother-
apy [20]. In a separate study of 31,748 women diagnosed
with breast cancer, anthracycline chemotherapy wasassociated with the development of cardiomyopathy (haz-
ard ratio [HR] 2.48, 95% CI 2.1 -2.93) and CHF (HR 1.38,
95% CI 1.25-1.52) [21].
In addition to CHF, patients exposed to anthracyclines
experience other CV events including MI and stroke. In
the CCSS cohort, children treated with anthracyclines
developed coronary artery disease (CAD; RR 10.4, 95%
CI 4.1-25.9) and cerebrovascular accidents (RR 9.3, 95%
CI 4.1-21.1) more frequently than their siblings without
cancer [22-26]. Similarly, in women over the age of
65 years treated with adjuvant anthracycline chemother-
apy for Stage I or II breast cancer, MI, stroke, and other
CV events were the primary cause of death in those sur-
viving 5 years beyond initiation of their treatment [8].
In adults, the combination of anthracyclines and radi-
ation therapy further increases CV events, particularly
MI. In the British National Lymphoma Investigation
database, a higher incidence of MI was noted in survi-
vors of Hodgkin’s disease who received radiation therapy
and anthracycline-based chemotherapy [27]. The RR of
death due to MI after radiation therapy ranged from 1.6
to 9.5 depending on radiation type and the associated
chemotherapy regimen utilized in the treatment plan
[27]. Furthermore, the RR of death due to MI was 4.1 in
the first year after treatment and remained elevated at
2.5 for more than 25 years after treatment.
Similar late risks of cardiac death were noted in 1,080
patients with Hodgkin’s lymphoma aged ≤50 years. In
these patients, radiation and chemotherapy were associ-
ated with cardiac mortality (RR 3.2 [1.9-5.2]) that
remained elevated (RR 4.5 [1.2-11.6]) 20 years after
treatment [28]. Overall, as described by Yeh et al., the
cumulative dose of anthracycline, the concomitant ad-
ministration of other cardio-toxic agents, prior radi-
ation therapy, female gender, increasing age, or the
presence of diabetes or hypertension are risk factors
for developing cardiovascular injury upon receipt of
anthracycline based chemotherapy with or without ra-
diation therapy [29-33].
Tyrosine kinase inhibitors - trastuzumab
Tyrosine kinases modulate cellular growth, differenti-
ation and metabolism [34]. Inhibitors of tyrosine kinases
have been associated with down regulation of many can-
cer cell related functions [35]. In general, these agents
are of two broad types: monoclonal antibodies, such as
trastuzumab and bevacizumab, and small molecule
inhibitors, such as lapatinib, imatinib, sorafenib, and
sunitinib. Over the past 5 to 10 years, it has been recog-
nized that many of these agents are also associated with
several adverse CV related abnormalities including
microvascular injury, hypertension, and LV dysfunction
[35,36]. The administration of the tyrosine kinase inhibi-
tor trastuzumab to women with HER2-positive breast
Table 1 Cancer therapeutic agents, risk factors, mechanisms, and manifestations of cardiotoxicity
Therapeutic
agent
Therapeutic indications Risk factors Mechanisms Manifestations of
cardiotoxicity
Anthracyclines
Doxorubicin Breast cancer Concurrent chemotherapy Cellular apoptosis induction Early
Daunorubicin Gastric Dosing schedules ETC. uncoupling CHF/LV dysfunction
Epirubicin Leukemias Elderly Iron complexation Myocardial ischemia/infarction
Idarubicin Lung cancer Women Lipid peroxidation of
myocyte
Pericarditis/myocarditis
Lymphomas Prior radiation membranes QT prolongation
Ovarian IV administration Nuclear DNA damage ST-T wave abnormalities




Mitoxantrone AML Unknown ROS formation Arrhythmias
CHF
Breast cancer Myocardial ischemia/infarction
NHL
Antimetabolites
5-Fluorouracil Breast cancer Underlying CV disease Endothelial cell damage Arrhythmias
Colorectal cancer Vasospasm CHF
Pancreatic cancer Myocardial ischemia/infarction
Antimicrotubules





Vinca alkaloids Leukemias Unknown Possible vasospasm Autonomic neuropathy
Vinblastine Lymphomas Hypotension
Vincristine Nephroblastoma Myocardial ischemia/infarction
Raynaud’s phenomenon
Alkylating agents




Cisplatin Germ cell tumors Elderly Coronary artery fibrosis Early
Lung cancer Prior mediastinal irradiation Hypokalemia CHF
Lymphomas Use for metastatic testicular Hypomagnesaemia Myocardial ischemia/infarction
Ovarian cancer cancer Late




Cyclophosphamide Leukemias High dose regimens Endothelial capillary damage
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Table 1 Cancer therapeutic agents, risk factors, mechanisms, and manifestations of cardiotoxicity (Continued)
CHF/LV dysfunction





Prior anthracyclines Hemorrhagic pericarditis
LVH
Ifosfamide Lymphomas High dose regimens Myocardial fiber
fragmentation
Arrhythmias
Various solid tumors Use for lymphomas CHF
Biological agents
Interferon-α Leukemias Unknown Early
Lymphomas Arrhythmias
Melanoma Hypertension
Various solid tumors Late
Cardiomyopathy
Interleukin-2 Melanoma Unknown Early











Prostate cancer Men over 65 Development of metabolic CAD
Underlying CV disease syndrome CHF/LV dysfunction
Dyslipidemia Myocardial ischemia/infarction




Breast cancers Unknown Dyslipidemia CAD













AML Unknown Hypomagnesaemia Arrhythmias with QT
prolongation
Pericardial effusion





Various malignancies Prior high doses of radiation Fibrosis caused by
inflammatory
Early
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Table 1 Cancer therapeutic agents, risk factors, mechanisms, and manifestations of cardiotoxicity (Continued)
Underlying CV disease changes Pericarditis/Pericardial effusion












HER-2 (−) breast cancer Possible decrease in nitric
oxide and
CHF
Lung cancer prostaglandin production HTN




Lapatinib HER-2 (+) breast cancer Use with anthracyclines Inhibits HER-2 and EGFR LV dysfunction
QT prolongation
Sorafenib HCC Use with anthracyclines Unclear, but may induce
apoptosis in cardiomyocytes,















Prior mediastinal irradiation CHF
Underlying CV disease Immune-mediated
destruction of cardiomyoytes
caused by selective binding
to HER-2 protein
LV dysfunction
Use with anthracyclines Late
Cardiomyopathy
AML acute myeloid leukemia, APL acute promyelocytic leukemia, CAD coronary artery disease, CHF congestive heart failure, CML chronic myeloid leukemia, CV
cardiovascular, EGFR epidermal growth factor receptor, ETC. electron transport chain, GIST gastrointestinal stromal tumor, HCC haptocellular carcinoma, HER human
epidermal growth factor receptor 2, HTN hypertension, LV left ventricle, LVH left ventricular hypertrophy, NHL non-Hodgkin’s lymphoma, RCC renal cell carcinoma,
ROS reactive oxygen species, SCD sudden cardiac death, VEGF vascular endothelial growth factor.
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tions in left ventricular ejection fraction (LVEF) [36].
Piccart-Gebhart, et al. identified the incidence of clinical
CHF or a subclinical deterioration of LVEF, defined as a
decrease in LVEF by 10% [37], to be 1.7% and 7%, respect-
ively, in women receiving trastuzumab. In a separate
study by Seidman, et al. cardiac dysfunction, defined
as symptomatic CHF or an asymptomatic deterioration in
LVEF of 10%, occurred in 27% of women who received
trastuzumab versus 8% receiving an anthracycline/cyclo-
phosphamide combination [16]. Cardiac dysfunction with
trastuzumab has been previously reported to occur in 13%
of women as opposed to only 1% of women who received
paclitaxel without trastuzumab [16].Anthracycline cardiotoxicity appears to be potentiated
by the concomitant administration of trastuzumab. This
particular combination is associated with the develop-
ment of severe LV systolic dysfunction, and as a result,
these agents are now administered in series (as opposed
to simultaneously) when utilized to treat breast cancer.
Furthermore, some trials have shown that increasing the
duration between anthracycline and trastuzumab admin-
istration reduces the incidence of LV dysfunction during
treatment for breast cancer [16,38].
Hormone deprivation therapies
In women with breast cancer or men with prostate can-
cer, the application of hormone deprivation therapies
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gonadotropin releasing hormone [GnRH] agonists, anti-
androgens, or orchiectomy in men) have dramatically
improved cancer-related survival and reduced cancer-
related recurrence [39-42]. Importantly however, it is in-
creasingly recognized that these therapies are associated
with CV events [43,44]. Androgen deprivation therapy
(ADT) is associated with the development of peripheral
arterial disease (PAD) and cerebrovascular disease in-
cluding stroke or transient ischemic attack (TIA) [45].
Among 182,757 men >66 years in age, ADT was associated
with a 5-year increased incidence of PAD upon receipt of
GnRH agonists (adjusted HR 1.16, 95% CI 1.12–1.21) or
after bilateral orchiectomy (adjusted HR 1.13, 95% CI
1.02–1.26) [45]. Both therapeutic strategies were associated
with an increase in venous thromboembolism (adjusted
HR 1.10, 95% CI 1.04–1.15; and adjusted HR 1.27, 95% CI
1.11–1.45, respectively) [45]. Prior studies have reported
that PAD develops shortly (as early as 1 to 4 months) after
ADT initiation and is often accompanied by an increase in
incident diabetes and serum lipoprotein abnormalities.
Multiple studies have confirmed an increased risk of
stroke/TIA after receipt of GnRH agonists, oral anti-
androgens or bilateral orchiectomy [46,47]. Among
22,310 men with prostate cancer followed for an average
of 3.9 years, ADT use was associated with the development
of stroke/TIA, specifically GnRH agonists (adjusted RR
1.18, 95% CI 1.00–1.39), oral anti-androgens (adjusted RR
1.47, 95% CI 1.08–2.01), and those who underwent bilateral
orchiectomy (adjusted RR 1.77, 95% CI 1.25– 2.39) [48].
The risk was not modified based on the presence of under-
lying cardiac risk factors with the highest risk seen in men
<65 years of age (adjusted HR 2.47, 95% CI 1.24-4.47).
In post-menopausal women, the administration of aro-
matase inhibitors reduces breast cancer recurrence
[42,49]. The etiology of this reduction is felt to be re-
lated to the severe reduction in circulating estrogens to
near unmeasurable levels [40]. It is becoming increas-
ingly recognized, however, that vascular disease and associ-
ated CV events are becoming more prevalent upon receipt
of aromatase inhibitors. In a meta-analysis of seven trials that
included 30,023 patients comparing aromatase inhibitors
and tamoxifen, longer durations of aromatase inhibitor use
was associated with increases in the odds ratios of develop-
ing CV disease (OR 1.26, 95% CI 1.10-1.43, p < 0.001) [39].
In summary, for some individuals, traditional and newer
therapeutic interventions for cancer (Table 1) can promote
a variety of both cardiac (CHF) and vascular (MI, stroke,
PAD) associated disorders. With the emergence of these
disorders affecting multiple components of the CV system,
there exists a unique opportunity to utilize imaging to
both diagnose and guide therapeutic interventions to diag-
nose and then guide the administration of therapeutic in-
terventions to prevent these untoward effects.Identification of cardiac toxicity
For the heart, several strategies have been utilized to
identify myocardial injury related to the administration for
cancer [50]. Upon the first recognition of anthracycline-
related myocardial dysfunction, endomyocardial biopsies
were performed to identify histopathologic evidence of
myofibrillar loss, vacuolization and extracellular loss
[51,52] and thereby confirm or refute the presence of
cardiotoxicity. Importantly however, this form of monitor-
ing became impractical for widespread clinical application
as the technique required an invasive procedure that was
not well-suited for repetitive examinations [50].
In the 1970s and 1980s, serial multigated nuclear radioiso-
tope studies or MUGA exams were serially implemented to
detect LV systolic dysfunction in patients treated with
anthracycline-based chemotherapy [53,54]. Evidence of de-
terioration in LVEF on MUGA scans during receipt of
anthracycline chemotherapy was associated with the devel-
opment of CHF [53,55]. Today, many of the existing man-
agement protocols rely on serial measures of LVEF by
MUGA or transthoracic echocardiography to identify che-
motherapy or immunotherapy induced reductions in LV
ejection fraction [56,57]. Importantly however, distinguishing
relatively small changes in LVEF related to cardiotoxicity
from those related to variance in the technique can be prob-
lematic. As a result, more advanced transthoracic echocardi-
ography (strain or diastolic function) assessments, [58] with
or without concomitant serum biomarkers (such as serum
troponin I levels [59,60]) have been utilized with a goal of in-
creasing detection of early evidence of cardiac injury after
chemotherapy [61,62]. The goal of these strategies is to iden-
tify those at risk of future CV events in order to implement
therapy to prevent these events.
It is important to note, however, that difficulties remain
with some of these newer quantitative strategies. Echocardi-
ography can be difficult to reliably perform longitudinally
over time due to body habitus, prior radiation treatment, or
prosthetic implants, and therefore, it can be difficult to ob-
tain adequate images from reproducible slice positions in a
reliable fashion. While serum biomarkers can be easily ac-
quired, these tests can lack specificity for cardiac injury re-
lated to the administration of therapy for cancer. Reduced
specificity of identification of chemotherapy-related cardiac
injury can lead to the unnecessary premature termination of
chemotherapy that prevents an individual cancer patient
from realizing the full benefit of his or her medical regimen.
Uniquely, CMR is well-suited to impact the detection of
CV injury after receipt of cancer treatment. CMR does not
incorporate ionizing radiation, thus is useful for repetitive
evaluations [63]. During a single exam, both the heart and
vasculature can be simultaneously assessed, an important
feature when evaluating patients receiving multiple therap-
ies that can promote injury to multiple components of the
CV system, such as cardiomyocytes and arterial endothelial
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after the administration of anthracycline chemotherapy
[64,65]. In addition, CMR can be utilized to detect multiple
aspects of a disease process by characterizing tissue [66],
measuring function [67], and identifying structural or meta-
bolic abnormalities [58] that can be impacted by the treat-
ment of cancer.
CMR to detect CV related injury
The role of CMR in identifying cardiotoxicity can be di-
vided into 5 broad categories (Figure 1A and B):
(1)The detection of cardiac anatomic or structural
abnormalities including valvular lesions, pericardial
disease, or evidence of metastasis;
(2)The identification and surveillance of myocellular injury;
(3)The surveillance of ventricular function;
(4)The assessment of vascular injury; and
(5)The evaluation of skeletal muscle injury.
We discuss these categories in more detail in the sec-
tions below.Valvular and pericardial disease
In addition to cardiomyopathy and development of
CAD, valvular and pericardial involvement has also
been identified as progressive complications occurring
late (i.e. 15–20 years) after exposure to chemotherapy
and radiation therapy [68]. Schellong, et al. have shown
that in 1,132 survivors of Hodgkin’s disease who re-
ceived anthracycline and radiation before 18 years of
age, valvular defects were diagnosed most frequently,
followed by CAD, cardiomyopathies, conduction disor-
ders, and pericardial abnormalities with median inter-
val between therapy and onset of cardiac disease at
20 years. At 25 years post chemotherapy and radiation
therapy, the cumulative incidence of cardiac disease
was 0.14, valvular disease was 0.09 and pericardial dis-
ease was 0.05 [69]. Aortic regurgitation was the most
common abnormality identified in this cohort. Using
echocardiography, in 116 patients, Wethal, et al. have
identified 33% progression of aortic regurgitation (de-
fined as new onset of aortic regurgitation on follow-up,
or increase by one grade of severity) and 39% develop-
ment of aortic stenosis over 12 years in young survivors
(median age 22 years) of Hodgkin’s lymphoma exposed
to anthracyclines or radiation therapy. In a similar
study of 1,249 survivors of Hodgkin’s lymphoma, abso-
lute excess risks of requiring valve replacement or
pericardiectomy/pericardiocentesis were 14.1 and 4.7
per 10,000 person-years, respectively. Extremes of age
(the very old and the very young) as well as male gen-
der were predictors for these cardiac events [70].Cardiac and pericardiac metastases
In addition to detection of valvular or pericardial anatomic
abnormalities, CMR is useful in detecting tumor metastasis.
While primary tumors involving the heart are relatively rare
[71], metastatic involvement is not uncommon [65]. Metas-
tases can occur through direct invasion, lymphatic or
hematogenous spread, or transvenous extension [71]. Me-
tastases to the heart and pericardium are identified at aut-
opsy in 10%–12% of all patients with malignancies [71,72].
The most common cardiac manifestation is development of
a pericardial effusion which occurs through direct invasion
or lymphatic spread. Due to proximity, lung cancer is a
common etiology of metastases to the heart and pericar-
dium. In addition, breast tumors, malignant melanoma,
renal cell carcinoma, mediastinal lymphomas, and leuke-
mias can metastasize to the heart. While these are initially
identified by echocardiography, CMR offers volumetric
coverage of the entire heart and provides the necessary
means to characterize the abnormal metastatic tissue
through the use of cine imaging (see Additional file 1), T2
and T1 mapping, gadolinium enhanced perfusion, and late
gadolinium enhancement as shown in Figure 2. These tech-
niques facilitate the differentiation of a malignant tumor in
comparison to a lipoma, thrombus or pericardial cyst.
Myocellular injury
Of all the chemotherapeutic agents, anthracyclines have
been the most extensively studied in terms of myocardial
histopathologic changes in the short and long-term.
As shown by Billingham and Isner, et al. [52,73] some
individuals do not, whereas others do, exhibit evi-
dence of myocellular injury (myofibrillar loss, myocyte
vacuolization, cellular necrosis and perivascular and
interstitial fibrosis) after anthracycline exposure. With
myocyte loss and interstitial edema, there is an expansion
of the myocardial extracellular space and thereby the vol-
ume of distribution of water. This leads to the prolonga-
tion of T1 and T2 and thus increased signal intensity on
T1 and T2 weighted images and signal prolongation (in
msec) on T1 and T2 maps.
Evidence that changes in T1 signal could be appreci-
ated with CMR were identified as early as 1987 when
Thompson, et al. reported changes in pre-contrast T1 in
a model of chronic adriamycin cardiotoxicity (Table 2) [74].
These investigators identified a significant prolongation of
pre-contrast T1 in an ex-vivo model of chronic adriamycin
toxicity in rats. In these same animals, changes in T2 were
absent. The results of this study also identified abnormal-
ities in myocardial energy metabolism using P31 nuclear
magnetic resonance [58]. In this chronic adriamycin tox-
icity model, hemodynamic stress in the form of rapid atrial
pacing was administered. Decreased myocardial phospho-
creatinine levels were noted after hemodynamic stress
in both the adriamycin-treated and the control rats.
igure 1 Cardiac toxicity by type of structure affected, along with causative cancer therapies is listed below. Valvular, pericardial and m ardial disease is shown in A, while vascular




















Figure 2 Imaging of cardiac metastases. Images from a patient with lung cancer with pericardial metastases. Panel A shows an axial slice of the heart
acquired by steady-state free precession imaging. The red arrows point to the circumferential pericardial mass, which is hypointense and encases the entire right
atrium, right ventricle and left ventricle. Panel B shows a cine image of the pericardial mass in a short-axis orientation (an additional movie file shows the cine
series in motion [see Additional file 1]). In addition to the circumferential extent of the mass, the anterolateral wall of the left ventricle and the free wall of the right
ventricle are tethered to the mass with reduced wall thickening and motion (arrows). Panel C shows a T2 weighted image in the same short-axis orientation. The
red arrows point to the hyperintense mass. Panel D shows a delayed enhancement image of the mass in the short axis orientation. The red arrow points to the
areas of hyperenhancement within the mass. The blue arrow points to the necrotic areas within the mass which are hypoenhanced with low signal intensity.
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and impartial recovery of the phosphocreatinine levels
compared to controls. Thus after chronic receipt of
adriamycin, both T1 tissue characteristics and cellular me-
tabolism became abnormal after stress.
The observation of increased myocardial T1 on pre-
contrast images was confirmed by Cottin, et al. as early
as 1 week after administration of adriamycin (Table 2)
[75]. This group also noted an increase in myocardial
water content, and dissimilar to the Thompson results,
an increase in T2, localized to the lateral free wall. These
abnormalities occurred prior to deterioration in LVTable 2 Changes in Myocardial signal characteristics after can







T1 changes, no T2
changes





T1 and T2 changes Ex vivo invers



















recoverysystolic performance. This group also identified abnor-
malities of lipid peroxidation concomitant with the ob-
served increase in myocardial T1 and T2 signal.
Similarly, abnormalities in signal intensity on post-
contrast T1 weighted images were noticed in human
studies by Wassmuth, et al. [76]. This group of investiga-
tors used contrast enhanced spin echo in 22 patients
who were imaged at 3 and 28 days after receipt of
anthracycline chemotherapy. Higher myocardial signal
intensities were noted as early as 3 days after receipt of
anthracycline chemotherapy and predicted a future drop









Prolongation of pre-contrast T1 and T2.
nced Spin Humans,
n = 79






Higher signal intensity than control rats.
This occurred early after chemotherapy and
prior to a drop in the LVEF.
This increase in signal intensity was
associated with microscopic evidence of
cell injury.
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after receipt of anthracycline chemotherapy.
Subsequently, with the advent of inversion recovery gradi-
ent recalled echo (GRE) sequences and the ability to identify
myocardial fibrosis with gadolinium contrast, a study was
performed by Lightfoot, et al. with a larger number of ani-
mals to assess the changes in myocardial T1 after varying
doses of the anthracycline doxorubicin (Table 2) [77]. The
changes in signal intensity in post-contrast T1 weighted im-
ages in 40 rats exposed to two different doses of doxorubicin
(1.5 and 2.5 mg/kg/week) were measured and compared to
that from animals that received saline. Animals that experi-
enced a drop in the LVEF after receipt of low or high doses
of doxorubicin demonstrated higher mean signal intensity
measured in the post-gadolinium T1 weighted inversion re-
covery images of the LV myocardium relative to those ani-
mals whose LVEF was maintained (Figure 3). Furthermore,
increases in signal intensity during early measurement
points were 80% sensitive and 82% specific for forecasting a
future drop in LVEF. As shown in Figure 3, animals with
higher signal intensities were found to have typical micro-
scopic evidence of myocellular injury due to myocardial
vacuolization and the accumulation of intra- and extracellu-
lar edema. Animals without cardiac dysfunction exhibited
normal signal intensities and no histopathologic evidence of
myocellular injury (Figure 3).Figure 3 Correlation of T1 signal intensity change after anthracycline
histograms and histopathology of the myocardium before and after receip
histograms of the number of pixels (y-axes) and intensities (x-axes) in indiv
(top middle), and DOX with an EF drop (top right). Below the histograms a
animals. As shown, mean intensity increased in the animals that had a drop
from Lightfoot, et al. Circ Cardiovasc Imaging 2010 [77].With myocyte loss and interstitial edema, there is an ex-
pansion of the myocardial extracellular space and hence
the volume of distribution of gadolinium contrast. This en-
ables incorporation of these T1 mapping techniques for as-
sessment of diffuse myocardial fibrosis in routine clinical
studies. While conventional delayed enhancement imaging
is excellent for the detection of focal myocardial fibrosis,
this requires nulling of the remaining myocardium render-
ing it more difficult to assess diffuse myocardial fibrosis.
Multiple studies have confirmed the utility of T1 mapping
before and after gadolinium to identify the myocardial par-
tition coefficient of gadolinium and thereby the myocardial
extracellular volume fraction (ECVF) [78-80]. Messroghli,
et al. have developed accurate T1 mapping techniques to
be performed in a single breathhold [81-83], and Flett,
et al. have studied alternative T1 mapping techniques and
found an excellent correlation between diffuse fibrosis and
the histological collagen volume fraction in patients with
myocardial hypertrophy due to aortic stenosis or hyper-
trophic cardiomyopathy [84]. In patients with cardiomyop-
athy, the myocardial ECVF assessment has prognostic
value beyond assessment of LVEF [85]. Whether similar
prognostic value of the myocardial ECVF can be assessed
in cancer survivors is an area of ongoing study.
In summary, CMR has the potential to assess early car-
diac injury by using T2 mapping and pre- and post-exposure with histopathologic changes in the myocardium. Serial
t of anthracycline. On the top portion of the figure are shown 4-week
idual animals after receipt of NS (top left), DOX without an EF drop
re 40× hematoxylin and eosin histopathologic images from the same
in EF corresponding to vacuolization (arrows, bottom right). Reprinted
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abnormalities that precede functional impairment offers an
opportunity to study the benefit of starting cardioprotective
agents before overt functional deterioration.
Ventricular function
With the realization that evidence of myocardial injury due
to the administration of anthracyclines could be appreciated
during invasive endomyocardial biopsies or from diagnostic
catheterization procedures, investigators sought to develop
non-invasive methodologies to accomplish early detection of
chemotherapy-related myocardial injury. In 1979, Alexander,
et al. utilized quantitative, multi-gated radionuclide angio-
cardiography (or MUGA) scanning to serially assess LVEF
in patients scheduled to receive doxorubicin for treatment
of cancer. In a cohort of 55 individuals, a decline in LVEF by
at least 15% to a final value of <45% was associated with the
development of CHF in patients receiving >350 mg/m2 of
anthracycline chemotherapy [53,86]. Soon thereafter, other
investigators confirmed these findings [57].
As a result of these and other early non-invasive im-
aging studies, guidelines were published in 1992 that
highlighted the use of LVEF measurements to screen and
monitor patients for the development of cardiotoxicity
and chemotherapy associated CHF [57,86]. These guide-
lines included an assessment of baseline LVEF prior to
chemotherapy followed by subsequent LVEF measure-
ments depending on the frequency and cumulative
anthracycline dose prescribed. During serial surveillance,
if a patient developed a deterioration in LVEF, then the
risk of developing CHF was elevated and therapeutic
interventions were suggested. It was also recognized that
the surveillance strategy could be modified due to the pres-
ence of potential additional risk factors for anthracycline-
based myocardial injury. These risk factors included the
application of mediastinal radiation, age (the very young
and those with advanced age), pre-existing heart disease,
and the associated administration of cyclophosphamide.
Today, the majority of these early established guidelines
are pervasive in the application of clinical care for patients
that will receive anthracycline-based chemotherapy for the
treatment of cancer.
Recent trials of newer cancer therapies that also pro-
mote cardiac injury such as trastuzumab, also routinely
monitor LVEF with echocardiography or MUGA scanning
to detect early deteriorations in LVEF that predispose one
to develop CHF [36]. Guidelines have been published
for the surveillance of LVEF during trastuzumab or
other cancer therapies by the UK National Cancer In-
stitute [87], and by the European Society of Medical
Oncology [88]. In addition to baseline assessments of
LVEF, additional assessments are recommended at
3, 6, and 9 months after treatment with anthra-
cyclines, and at 4 monthly intervals for trastuzumab.Furthermore, the UK National Cancer Institute guide-
lines detail the use of a “traffic light” system to en-
able detection and management of cardiotoxicity with
trastuzumab in which the therapeutic administration
of angiotensin converting enzyme inhibitors is directed
through measurement of LVEF.
CMR is well-suited to assess LVEF prior to and during
receipt of potentially cardiotoxic chemotherapy. The
ability to acquire images in multiple tomographic planes
without limitations imposed by body habitus enable
CMR LVEF assessments to be performed in patients
who may have undergone prior surgery to pericardiac
regions including the chest, lungs and mediastinum.
Importantly, CMR accurately measures the ventricular
volumes that contribute to the LVEF calculation. Com-
pared with two-dimensional (2D) echocardiography, the
inter-study coefficient of variability for assessment of LV
volumes, function and mass was superior for CMR
among healthy individuals, as well as those with heart
failure or left ventricular hypertrophy [89]. The inter-
study reproducibility for CMR measured end-systolic
volume was 4.4% to 9.2% (versus 12.7 to 20.3% for 2D
echocardiography), for ejection fraction was 2.4% to
7.3% (versus 8.6% to 9.4% for 2D echocardiography), and
for LV mass was 2.8% to 4.8% (versus 11.6% to 15.7% for
2D echocardiography) [89]. Similarly, low inter-observer
variability was noted in a comprehensive study compar-
ing CMR volumes derived by cine and spin echo CMR
[90]. Abnormalities of left ventricular end-diastolic vol-
ume (LVEDV), which could be due to changes in LV pre-
load, can be detected with CMR. This LVEDV assessment
is particularly important in patients receiving treatment
for cancer who may exhibit altered pre-load due to poor
oral intake or excessive nausea and vomiting. In
addition, CMR can accurately identify abnormalities
of left ventricular end-systolic volume (LVESV), which
reflect abnormalities of myocardial contractility. Fi-
nally, the 3-dimensional acquisitions of these LV vol-
umes and EF are very useful when cardiac function
becomes reduced and the left ventricle assumes an
abnormal shape that may differ from a prolate ellips-
oid that is often assumed for the calculation of LVEF
using a 2D technique.
In addition to determinations of LV volumes and EF,
other measures of LV systolic and diastolic function can
be obtained during the same CMR examination. For ex-
ample, myocardial strain, a unitless measure of myocar-
dial deformation can be assessed during ventricular
systole or during ventricular diastole (strain rate). Both
of these measures may provide incremental diagnostic
information relative to LV function [91]. These values
have been useful in assessing and identifying individuals
with abnormalities of LV function due to ischemic [92]
and non-ischemic cardiomyopathies [93] as well as other
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oidosis [94,95]. Recently, Drafts, et al. acquired serial as-
sessments of LV volumes and myocardial strain to
identify abnormalities of LV performance during receipt
of anthracycline chemotherapy. In 55 individuals sched-
uled to receive an anthracycline-based chemotherapeutic
regimen for leukemia, lymphoma, or breast cancer, Drafts,
et al., found that measures of LV systolic performance
(LVESV and myocardial strain) deteriorated early (even
after the first dose) of the administration of anthracycline-
based chemotherapy (Figure 4) [96]. Moreover, these dete-
riorations remained present after the discontinuation of
anthracycline chemotherapy. These data highlight the po-
tential utility of CMR for identifying abnormalities of LV
performance that indicate ongoing cardiac dysfunction
due to toxicity from anthracycline-based regimens. Com-
bining both these advanced functional measures with myo-
cardial tissue characterization techniques (such as the
mapping technologies mentioned previously) could provide
a new strategy for identifying those at risk of CHF and
thereby guide therapeutic interventions to reduce these
risks. Currently, a large multi-center randomized trial is un-
derway utilizing CMR to assess the efficacy of conventional
heart failure drugs such as ACEIs and beta-blockers in pa-
tients receiving trastuzumab therapy for breast cancer [97].
In addition to myocardial strain and volume assess-
ment, promising techniques being developed include dif-
fusion tensor imaging for the identification of impaired
myocardial mechanics, [98] for example, impaired tor-
sion and spectroscopy for assessing abnormal myocardial
metabolism [99]. These techniques are currently being
studied in hypertrophic cardiomyopathy and could be
potentially used in patients exposed to cancer therapies,
to identify myocardial abnormalities prior to the onset
of overt systolic dysfunction.Figure 4 Serial changes in LV volumes, myocardial strain and LVEF af
changes in left ventricular (LV) end diastolic volume (left y-axis; panel A) an
(left y-axis; panel B); serum Troponin-I (right y-axis; panel B); pulse wave ve
strain (right y-axis; panel C). The mean ± the standard error are shown. The
serum Troponin-I while at the same time a decrease in LV ejection fraction
after administration of low to moderate doses of anthracycline-based chemVascular injury
It is important to recognize that in addition to the devel-
opment of CHF, many treatments for cancer also predis-
pose individuals to the development of CV events
related to abnormalities of the vascular system. These
CV events include the development of MI, PAD, and
stroke. Several different cancer therapies have been
shown to promote these vascular related events.
Hormonal therapy such as ADT is associated with an
increased incidence of MI, PAD, and stroke [45,46,100].
Tyrosine kinase inhibitors such as bevacizumab, sorafinib
and sunitinib promote hypertension [100-103]. Recently,
Chaosuwannakit, et al. demonstrated that proximal
aortic wall stiffness increased 3 months after receipt
of anthracycline-based chemotherapy compared to age
matched controls (Figure 5) [64]. Among the anthracycline-
based chemotherapy recipients, the increased aortic stiff-
ness was noted even after controlling for factors such as
age, gender, diabetes, hyperlipidemia and hypertension. The
magnitude of the increase was equivalent to that associated
with aging the CV system by 10–20 years.
Two additional features of this increase in stiffness are
noteworthy. First, this occurred soon after administra-
tion of chemotherapy and therefore is dissimilar to the
more chronic causes of stiffening (e.g. atherosclerosis)
more commonly observed. Recently, Eckman, et al. iden-
tified early histopathologic evidence of coronary artery
microcirculatory endothelial damage in an animal model
of anthracycline cardiotoxicity [104]. Perhaps endothelial
damage to the vasa vasorum supply or on the luminal
surface of the aorta contributed to the abrupt increase in
aortic stiffening. Further research is needed in this area.
Second, the increases in aortic stiffening were not dose
dependent. This finding suggests there may be thresh-
olds of susceptibility to vascular dysfunction, and furtherter anthracycline exposure in human subjects. Time dependent
d LV end systolic volume (right y-axis; panel A); in LV ejection fraction
locity (PWV) (left y-axis; panel C); and mean mid wall circumferential
re was a substantive increase in LV end systolic volume, PWV, and
and mean mid-wall circumferential strain from baseline to six months
otherapy. Reprinted from Drafts, et al. JACC-Imaging 2012 [96].
Figure 5 Serial changes in aortic stiffness in chemotherapy
recipients. Chaosuwannakit, et al. demonstrated that pulse wave
velocity (PWV) increased in participants receiving cancer therapy.
PWV results for the control participants (A) and the participants
receiving cancer therapy (B). The increase in PWV observed in this
study is associated with a 3-fold increase in the risk of a future CV
event and consistent with a 10 to 20 year age associated increment
of the cardiovascular system. Reprinted from Chaosuwannakit, et al.
J Clin Oncol 2010 [64].
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bilities. These increases in aortic stiffness could have
important clinical ramifications. Abnormal increases in
proximal aortic stiffness have been associated with LV
hypertrophy, exercise capacity (particular in the elderly)
[105], and future CV events in those with diabetes,
hypertension, renal failure, and advanced age. It is im-
portant to note, however, that it is unknown whether
these increases in aortic stiffness are transient or
whether they reverse after changes in therapy.
Additional changes to the vascular system have been
reported upon receipt of treatment for cancer. These in-
clude the development of accelerated atherosclerosis and
abnormalities of peripheral arterial endothelial function.
In men treated for prostate cancer and post-menopausal
women treated for breast cancer, the administration of
ADT men and estrogen deprivation for women have been
associated with the development of metabolic syndrome,
diabetes, atherosclerosis, and CV events. Although not
studied previously, there is potential for CMR to be usedto identify the rapid progression of atherosclerosis by
identifying abnormalities of aortic or carotid arterial
wall thickness or the components of plaque compos-
ition (Figure 1B).
The administration of anthracycline-based chemother-
apy has been associated with abnormalities of peripheral
arterial and endothelial function. Endothelial function
can be assessed noninvasively through the assessment of
flow mediated arterial dilation (FMAD). CMR is highly
advantageous for the assessment of peripheral arterial
FMAD (Figure 1B). Phase contrast techniques that
measure both wall shear stress and arterial dilation can
be performed prior to, during, and after cuff inflation on
both the upper as well as the lower extremity. These
measures have been useful in identifying abnormalities
of FMAD in older individuals with heart failure due to a
reduced or preserved LVEF. At present, CMR FMAD
measurements have not been acquired in patients
treated for cancer. As the number of therapies targeted
toward the vascular supply of tumors increases, the
proven utility of CMR for assessing peripheral arterial
endothelial function may be useful for identifying unin-
tended injury to the native arterial circulation.Skeletal muscle function as a contributor to exercise
capacity and fatigue
Fatigue and muscle weakness are common among recip-
ients of chemotherapy, and often they persist for many
years after cessation of cancer treatment [106-108]. Per-
ceived fatigue and weakness is debilitating with a pro-
foundly negative impact on quality of life. In 33% of
women surviving treatment for breast cancer, fatigue is
progressive and severely limits the ability to return to
work [106]. In addition, fatigue may influence exercise
capacity, a known predictor of CV events. Patients who
received chemotherapy experience both fatigue and
exercise intolerance, and therapeutic interventions
that modify exercise capacity in cancer survivors also
improve fatigue [109]. In fact, physical activity >3
METS is associated with reduced CV related morbidity
and mortality in survivors of both breast and colon cancer
[110,111].
In those capable of normal ambulation, exercise cap-
acity is influenced during stress by changes in cardiac
output, arterial and microcirculatory function, and
skeletal muscle metabolism and function. CMR is well-
suited to assess all three of these components of exercise
capacity both at rest and during pharmacologic or exercise
induced stress. In elderly patients with heart failure
and preserved or reduced EF [112,113], CMR derived
information from these three components has been
utilized to understand mechanisms of disability and
exercise intolerance.
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and vascular abnormalities identified in Table 1, skel-
etal muscle dysfunction may also occur after treatment
for cancer. For example, doxorubicin potentiates direct
skeletal muscle weakness through generation of react-
ive oxygen species and TNFα signaling [114]. Anthra-
cyclines accumulate in skeletal muscle and have been
shown to decrease muscle force on direct muscle force
testing [115]. In addition they also cause loss of myofi-
brillar organization and interstitial edema [116]. To
date, the role of the skeletal muscle weakness in exer-
cise intolerance in chemotherapy recipients has not
been systematically addressed; however, skeletal muscle
energetics assessed at rest or after exercise with multi-
nuclear spectroscopy could be highly informative in
detecting abnormalities of ATP utilization that occur as
a result of the impact of oxidative stress on the working
mitochondria (Figure 1A). In addition, skeletal muscle
oxygen uptake can be studied with novel blood oxygen
level dependent (BOLD) MRI techniques. BOLD signal-
ing relies on the hemoglobin oxygen saturation [117].
During increased tissue perfusion at constant levels of
oxygen extraction, the oxyhemoglobin concentration is
higher, and a lower concentration of paramagnetic
deoxyhemoglobin is noted. This results in an increase
in the T2 and T2* signal (positive BOLD signal). Coup-
ling these BOLD assessments with measurements of
skeletal muscle level microcirculatory perfusion after
exercise using arterial spin labeling would be helpful to
delineate muscle oxygen extraction for given levels of
perfusion. In the calf of individuals with PAD, skeletal
muscle phosphocreatine recovery after exercise has
been shown to be diminished relative to control popu-
lations [118], and in combination with the measures of
perfusion, oxygen utilization, and skeletal muscle mass,
the incorporation of energetics could provide a moreTable 3 Unresolved issues in cancer survivors and possible te
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mechanics, i.e. Impaired torsion
Diff
Myocardial energy metabolism NM
Impaired exercise tolerance Arterial stiffness 4D
Fatigue Skeletal muscle injury NM
Fat/
Hypertension Endothelial dysfunction Flowcomplete and quite novel understanding of the etiology
of fatigue in cancer survivors (Figure 1A and B).
Future directions:
We have identified areas of research in cardiovascular
toxicity beyond the assessment of cardiac structure and
function, specifically to explore the mechanisms leading
to co-morbidities that have a delayed onset after the ini-
tial exposure to cancer therapeutics. Table 3 provides a
list of available newer MRI tools that can be utilized to
assess the etiology of fatigue, accelerated atherosclerosis
of the coronary, cerebral and peripheral vascular systems
in addition to accelerated stiffness of the entire vascular
system.
Conclusion
In summary, although cancer free survival is improving
for many individuals treated for malignancies, an unin-
tended consequence has been the emergence of cardio-
vascular events in the form of heart failure, myocardial
infarction, stroke, and peripheral arterial disease.
Temporally, it appears that these cardiovascular events
and underlying subclinical cardiovascular disease are
related to the therapies received for cancer. To this
end, the ability of cardiovascular magnetic resonance
to characterize and assess the function of the cardio-
vascular system is useful in identifying subclinical ab-
normalities of cardiovascular function that often
precede CV events. Several single center studies have
demonstrated the utility of CMR technologies to
identify this early subclinical cardiovascular injury.
Importantly however, further research is needed to
fully develop cardiovascular magnetic procedures that
both diagnose and also guide therapeutic interven-
tions to prevent cardiovascular event and also the
pronounced fatigue and related morbidities associated
with administration of therapy for cancer.chniques to address these issues
posed MRI technique
ll thickness of ascending, descending aorta, plaque characterization
onary flow reserve using quantitative myocardial perfusion
ll thickness of femoral arteries, BOLD imaging




Flow for assessing pulse wave velocity
R spectroscopy to assess for mitochondrial dysfunction in skeletal muscle
water separation to assess fat content
mediated arterial dilation
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